Get the Stockscreener App
564.17
2.11%
-11.90
Idexx Laboratories Inc stock is traded at $564.17, with a volume of 309.97K.
It is down -2.11% in the last 24 hours and up +3.27% over the past month.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
See More
Previous Close:
$576.07
Open:
$570.76
24h Volume:
309.97K
Relative Volume:
0.49
Market Cap:
$44.49B
Revenue:
$4.45B
Net Income/Loss:
$1.10B
P/E Ratio:
41.51
EPS:
13.591
Net Cash Flow:
$1.06B
1W Performance:
+0.07%
1M Performance:
+3.27%
6M Performance:
-21.17%
1Y Performance:
+8.72%
1-Day Range:
$561.15
$579.39
1-Week Range:
$536.14
$581.37
52-Week Range:
$513.02
$769.98
Idexx Laboratories Inc Stock (IDXX) Company Profile
Name
Idexx Laboratories Inc
Sector
Industry
Phone
(207) 556-0300
Address
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
564.05 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
533.43 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
204.02 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
271.09 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
132.00 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-31-25 | Upgrade | Stifel | Hold → Buy |
| Oct-01-25 | Initiated | UBS | Neutral |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-01-25 | Initiated | Jefferies | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | BTIG Research | Buy |
| Jan-30-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Dec-04-23 | Upgrade | Cleveland Research | Neutral → Buy |
| Aug-02-23 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Jul-25-22 | Downgrade | Stifel | Buy → Hold |
| Jul-21-22 | Upgrade | Goldman | Neutral → Buy |
| Jul-12-22 | Initiated | Piper Sandler | Overweight |
| May-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-08-22 | Initiated | Atlantic Equities | Overweight |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-17-21 | Initiated | Barclays | Overweight |
| Sep-09-19 | Initiated | Goldman | Neutral |
| May-23-19 | Initiated | Guggenheim | Buy |
| Nov-02-18 | Reiterated | BofA/Merrill | Buy |
| May-07-18 | Reiterated | Stifel | Buy |
| Jan-16-18 | Initiated | Piper Jaffray | Overweight |
| Aug-23-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-28-17 | Upgrade | CL King | Neutral → Buy |
| Feb-03-17 | Downgrade | Feltl & Co. | Hold → Sell |
| Sep-29-16 | Resumed | BofA/Merrill | Neutral |
| Aug-16-16 | Reiterated | Stifel | Buy |
| Aug-03-16 | Upgrade | Northcoast | Sell → Neutral |
| Jul-20-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-19-16 | Reiterated | Canaccord Genuity | Buy |
| Apr-01-16 | Initiated | CL King | Neutral |
| Mar-21-16 | Reiterated | Stifel | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Oct-29-15 | Reiterated | Stifel | Buy |
| Aug-28-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-13-15 | Reiterated | Stifel | Buy |
| Jul-23-15 | Reiterated | Canaccord Genuity | Buy |
View All
Idexx Laboratories Inc Stock (IDXX) Latest News
Global Livestock Monitoring Market to Reach $10.3 Billion by 2030, Driven by Digital Agriculture Transformation - GlobeNewswire Inc.
IDEXX Laboratories stock trades near record levels as companion animal diagnostics drive growth - ad-hoc-news.de
IDEXX Laboratories earnings preview: What to expect - MSN
Idexx Laboratories (IDXX) Shows Promising Growth Potential - GuruFocus
Is IDEXX Laboratories Inc (IDXX) a Bargain After 4.2% Drop? GF V - GuruFocus
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Why IDEXX Laboratories (IDXX) Stock Is Down Today - Moomoo
Donald TrumpIDEXX LABS UNSOLICITED Trump Trade on Mar. 23, 2026 - Quiver Quantitative
IDEXX Laboratories stock holds steady as diagnostics demand supports long-term growth - ad-hoc-news.de
IDEXX Laboratories Earnings Preview: What to Expect - inkl
Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating - marketscreener.com
IDEXX Laboratories focuses on diagnostics growth. Investors watch demand trends - ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories extends its diagnostics reach as a key S&P 500 health-tech name - ad-hoc-news.de
IDEXX Laboratories Does Not Need More Vet Visits, But It Needs More Tests Per Visit (IDXX) - Seeking Alpha
William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating - Moomoo
IDEXX Laboratories focuses on diagnostics growth. Business model supports long-term demand - ad-hoc-news.de
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories Stock: $876 Target Backed by Cancer Dx Adoption Across 7,500 Practices - TIKR.com
IDEXX Laboratories stock holds its focus on diagnostics. Investors watch the business mix. - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring a Potential 27% Upside for Investors - DirectorsTalk Interviews
The SNAP Pro AnalyzerIDEXX Laboratories leans on faster point-of-care diagnostics - ad-hoc-news.de
IDEXX Laboratories stock tracks its core diagnostics business - ad-hoc-news.de
IDXXIdexx Laboratories Inc Volatility & Greeks - Finviz
Enterprise value to EBIT forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories stock leans on its diagnostics base - Ad-hoc-news.de
IDEXX Laboratories focuses on diagnostics growth as investors watch long-term demand - ad-hoc-news.de
Price to sales forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories outlook as a diagnostics leader - ad-hoc-news.de
Price to earnings forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
Does IDEXX Laboratories (NASDAQ:IDXX) Deserve A Spot On Your Watchlist? - Moomoo
EULAV Asset Management's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
IDEXX Laboratories Inc (IDXX) Stock Up 3.8% and Still Undervalued -- GF Score: 96/100 - GuruFocus
IDEXX Laboratories to Release 2026 Second Quarter Financial Results - 01net
Press Release: IDEXX Laboratories to Release 2026 Second Quarter Financial Results - Moomoo
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell Midcap Value Benchmark - marketscreener.com
Is the Options Market Predicting a Spike in IDEXX Laboratories Stock? - Zacks Investment Research
Is IDEXX Laboratories stock underperforming the Nasdaq? - MSN
IDEXX Laboratories (IDXX) Stock Analysis: Uncovering a Potential 28.58% Upside for Investors - DirectorsTalk Interviews
IDEXX Laboratories with a clear strategy focus, shares anchored in the NASDAQ-100 - AD HOC NEWS
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Value Benchmark - marketscreener.com
The Catalyst Dx from IDEXX Laboratories Inc.compact chemistry analyzer for fast in-clinic results - AD HOC NEWS
IDEXX Laboratories, Inc.(NasdaqGS: IDXX) added to Russell 1000 Value-Defensive Index - marketscreener.com
IDEXX Laboratories opens the week with a clear consensus, NASDAQ-100 shares in a steady trend - Ad-hoc-news.de
IDEXX Laboratories focuses on long-term growth, shares in NASDAQ-100 healthcare peer group - Ad-hoc-news.de
New diagnostic test for kidney injury - DVM360
IDEXX Laboratories opens the week with earnings focus, shares steady - Ad-hoc-news.de
IDEXX Laboratories, Inc. Actuals & Estimates (NASDAQ:IDXX) - TradingView
IDEXX Laboratories, Inc. Actuals & Estimates (VIE:IDXX) - TradingView
IDXX Forecast — Price Target — Prediction for 2027 - TradingView
Idexx Laboratories Inc Stock (IDXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):